Chronic Fatigue Syndrome is a continued tiredness throughout life that is not relieved by sleep or rest. The cause of Chronic Fatigue Syndrome is unknown, but some think that it may be caused by a virus or inflammation in the nervous system. The main symptom of Chronic Fatigue Syndrome is extreme tiredness that keeps people out of activities and last at least 6 months. Other symptoms include muscle aches, headaches, and confusion. There is no cure for Chronic Fatigue Syndrome, but sleeping techniques and treatments for the symptoms are recommended. People with Chronic Fatigue Syndrome are more prone to developing depression and isolation.
Chronic Fatigue Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Chronic Fatigue Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 4211 products for the study of Chronic Fatigue Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Chronic Fatigue Syndrome is also known as chronic fatigue syndrome, postviral fatigue syndrome (disorder), myalgic encephalomyelitis, myalgic encephalitis, encephalitis, cfs.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.